View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC IT Research ... (+4)
  • ABGSC IT Research
  • Daniel Thorsson
  • Nikola Kalanoski
  • Simon Granath
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
Maria Vara
  • Maria Vara

BONESUPPORT: Closing a solid 2024

2024 saw BONESUPPORT further accelerate its market leadership with Q4 sales reaching SEK257m—up 49% YoY—driving FY sales to SEK898.7m (52% YoY), in line with guidance of 50% topline growth. In North America, CERAMENT G continued its strong performance, rising by approximately SEK22m QoQ to reach ar

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
Patrik Ling
  • Patrik Ling

Elekta (Hold, TP: SEK65.00) - Earnings miss and guidance cut

Elekta reported weaker earnings than we forecast and reduced its 2024/25 guidance. The company expects flat revenues (from mid-single digit growth) and lower adj. EBIT margin (from increasing margins). Order intake was strong, with c21% growth YOY driven by Elekta Evo and Elekta ONE. The share price reaction (down c9% on the reporting day) reflects the stock market’s caution’s regarding Elekta’s growth and margin progression, we believe. We reiterate our HOLD, but have cut our target price to SE...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
Patrik Ling
  • Patrik Ling

Elekta (Hold, TP: SEK70.00) - Focus on guidance for Q4

We are in line with consensus for Q3 and believe investors should focus on the guidance for Q4 and the full year, given the miss last year. 2024/25 is likely to be skewed towards Q4, which should be a ‘make or break’ quarter for the full year, despite the easy YOY comparable. We reiterate our HOLD and SEK70 target price.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Sten Gustafsson
Ebba Bjorklid
  • Ebba Bjorklid

Thule Group (Buy, TP: SEK450.00) - On track

Following the Q4 results, we have more confidence in the speed and magnitude at which Thule should be able to achieve a structurally higher EBIT margin due to its mix-shift (supported by new category launches), record new product launches, and the Quad Lock acquisition. Consequently, we reiterate our BUY and have increased our target price to SEK450 (445).

CTT Systems AB: 2 directors

Two Directors at CTT Systems AB bought 26,000 shares at between 227.500SEK and 228.950SEK. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Adrian Gilani
  • Karl Bokvist
ABGSC Consumer Goods Research ... (+3)
  • ABGSC Consumer Goods Research
  • Benjamin Wahlstedt
  • Fredrik Ivarsson

Thule Group AB: 2 directors

Two Directors at Thule Group AB bought/maiden bought 1,550 shares at between 363.800SEK and 363.980SEK. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...

ABGSC Consumer Goods Research ... (+3)
  • ABGSC Consumer Goods Research
  • Benjamin Wahlstedt
  • Fredrik Ivarsson
ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Adrian Gilani
  • Karl Bokvist
ABGSC Services Research ... (+2)
  • ABGSC Services Research
  • Simon Jönsson
Karl-Johan Bonnevier
  • Karl-Johan Bonnevier

Loomis (Buy, TP: SEK520.00) - Entering 2025 in strong fashion

Loomis’ Q4 results showed return to historically good form, with still-strong organic growth, the US operation excelling and Europe making a greater contribution. We have raised our 2025–2027e EPS by 3–8%, still viewing Loomis as a well-financed roll-up case, with the resources to drive sector consolidation and shareholder-friendly capital allocation. We reiterate our BUY, and have raised our target price to SEK520 (450).

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch